Phathom Pharmaceuticals Inc (PHAT) is now in the Overvalued zone, suggesting that its current forward PS ratio of 4.02 is considered Overvalued compared with the five-year average of -3.92. The fair price of Phathom Pharmaceuticals Inc (PHAT) is between -14.19 to -10.15 according to relative valuation method. Compared to the current price of 11.31 USD , Phathom Pharmaceuticals Inc By Overvalued By -211.46%.

Relative Value

Fair Zone

-14.19--10.15

Current Price：11.31

-211.46%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Phathom Pharmaceuticals Inc (PHAT) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Phathom Pharmaceuticals Inc (PHAT) has a current Price-to-Book (P/B) ratio of -2.64. Compared to its 3-year average P/B ratio of -1.27, the current P/B ratio is approximately 107.38% higher. Relative to its 5-year average P/B ratio of -2.47, the current P/B ratio is about 6.88% higher. Phathom Pharmaceuticals Inc (PHAT) has a Forward Free Cash Flow (FCF) yield of approximately -20.60%. Compared to its 3-year average FCF yield of -36.63%, the current FCF yield is approximately -43.77% lower. Relative to its 5-year average FCF yield of -32.61%, the current FCF yield is about -36.83% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PHAT competitors is -28.95, providing a benchmark for relative valuation. Phathom Pharmaceuticals Inc Corp (PHAT.O) exhibits a P/S ratio of 4.02, which is -113.87% above the industry average. Given its robust revenue growth of 94.12%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PHAT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PHAT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PHAT currently overvalued or undervalued?

Phathom Pharmaceuticals Inc (PHAT) is now in the Overvalued zone, suggesting that its current forward PS ratio of 4.02 is considered Overvalued compared with the five-year average of -3.92. The fair price of Phathom Pharmaceuticals Inc (PHAT) is between -14.19 to -10.15 according to relative valuation method. Compared to the current price of 11.31 USD, Phathom Pharmaceuticals Inc is Overvalued By -211.46%.

What is Phathom Pharmaceuticals Inc (PHAT) fair value?

PHAT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Phathom Pharmaceuticals Inc (PHAT) is between -14.19 to -10.15 according to relative valuation method.

How does PHAT's valuation metrics compare to the industry average?

The average P/S ratio for PHAT's competitors is -28.95, providing a benchmark for relative valuation. Phathom Pharmaceuticals Inc Corp (PHAT) exhibits a P/S ratio of 4.02, which is -113.87% above the industry average. Given its robust revenue growth of 94.12%, this premium appears sustainable.

What is the current P/B ratio for Phathom Pharmaceuticals Inc (PHAT) as of Mar 04 2026?

As of Mar 04 2026, Phathom Pharmaceuticals Inc (PHAT) has a P/B ratio of -2.64. This indicates that the market values PHAT at -2.64 times its book value.

What is the current FCF Yield for Phathom Pharmaceuticals Inc (PHAT) as of Mar 04 2026?

As of Mar 04 2026, Phathom Pharmaceuticals Inc (PHAT) has a FCF Yield of -20.60%. This means that for every dollar of Phathom Pharmaceuticals Inc's market capitalization, the company generates -20.60 cents in free cash flow.

What is the current Forward P/E ratio for Phathom Pharmaceuticals Inc (PHAT) as of Mar 04 2026?

As of Mar 04 2026, Phathom Pharmaceuticals Inc (PHAT) has a Forward P/E ratio of -12.29. This means the market is willing to pay $-12.29 for every dollar of Phathom Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Phathom Pharmaceuticals Inc (PHAT) as of Mar 04 2026?

As of Mar 04 2026, Phathom Pharmaceuticals Inc (PHAT) has a Forward P/S ratio of 4.02. This means the market is valuing PHAT at $4.02 for every dollar of expected revenue over the next 12 months.

PHAT Valuation